Targeting aberrant chromatin structure in colorectal carcinomas

Area of Science:

• Molecular Biology
• Cancer Research
• Epigenetics

Background:

• Epigenetic processes like DNA methylation and histone modifications regulate gene expression without altering DNA sequence.
• Neoplastic cells exhibit epigenetic alterations contributing to tumorigenesis.
• Colorectal cancer shows a distinct phenotype, the CpG island methylator phenotype (CIMP).

Purpose of the Study:

• To investigate the role of epigenetic changes in colorectal tumorigenesis.
• To understand the characteristics of CpG island methylator phenotype-positive colorectal cancers.
• To explore the therapeutic potential of reversing epigenetic alterations.

Main Methods:

• Analysis of epigenetic modifications in colorectal cancer.
• Characterization of CpG island methylator phenotype-positive colorectal cancers.
• In vivo and mouse model studies of epigenetic drug efficacy.

Main Results:

• CpG island methylator phenotype-positive colorectal cancers are associated with specific clinical and molecular features (female sex, older age, proximal location, mucinous histology, KRAS/BRAF mutations, wild-type p53, microsatellite instability).
• DNA methylation and histone modifications form reinforcing networks for gene silencing.
• DNA methylation inhibitors restored silenced pathways in vivo, and hypomethylation reduced tumorigenesis in a mouse model.

Conclusions:

• Epigenetic alterations play a critical role in colorectal cancer.
• Therapeutic reversal of epigenetic changes is a promising strategy.
• Drugs targeting DNA methylation and histone deacetylation warrant clinical testing in colorectal malignancy.